Imaging patients with kidney disease: How do we approach contrast-related toxicity?

Mark A. Perazella, Robert F. Reilly

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The approach to imaging patients with kidney disease with iodinated radiocontrast and gadolinium-based contrast has changed dramatically in recent times. The complications of these contrast agents, radiocontrast nephropathy and nephrogenic systemic fibrosis, respectively, underlie the changes in the imaging practice used in these patients. Rather than to completely avoid the use of these contrast agents, one must remain judicious in the choice of imaging modality in this group of patients. A prudent approach would be to (1) identify patients at high risk to develop contrast-related complications, (2) use noncontrast-based imaging techniques in these patients, as long as they are suitably diagnostic and safe and (3) if the risk:benefit ratio of the imaging information favors a contrast-based study, then appropriate prophylactic steps and use of contrast agents with the lowest risk of complication should be used after obtaining informed consent. This will allow one to maximize the diagnostic efficiency while also limiting the adverse effects.

Original languageEnglish (US)
Pages (from-to)215-221
Number of pages7
JournalAmerican Journal of the Medical Sciences
Volume341
Issue number3
DOIs
StatePublished - Mar 2011

Fingerprint

Kidney Diseases
Contrast Media
Nephrogenic Fibrosing Dermopathy
Gadolinium
Informed Consent
Odds Ratio

Keywords

  • Diagnostic imaging
  • Gadolinium
  • Kidney disease
  • Nephrogenic systemic fibrosis
  • Radiocontrast-induced nephropathy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Imaging patients with kidney disease : How do we approach contrast-related toxicity? / Perazella, Mark A.; Reilly, Robert F.

In: American Journal of the Medical Sciences, Vol. 341, No. 3, 03.2011, p. 215-221.

Research output: Contribution to journalArticle

@article{191c21fc1a654bce8efba1a0cdb2c648,
title = "Imaging patients with kidney disease: How do we approach contrast-related toxicity?",
abstract = "The approach to imaging patients with kidney disease with iodinated radiocontrast and gadolinium-based contrast has changed dramatically in recent times. The complications of these contrast agents, radiocontrast nephropathy and nephrogenic systemic fibrosis, respectively, underlie the changes in the imaging practice used in these patients. Rather than to completely avoid the use of these contrast agents, one must remain judicious in the choice of imaging modality in this group of patients. A prudent approach would be to (1) identify patients at high risk to develop contrast-related complications, (2) use noncontrast-based imaging techniques in these patients, as long as they are suitably diagnostic and safe and (3) if the risk:benefit ratio of the imaging information favors a contrast-based study, then appropriate prophylactic steps and use of contrast agents with the lowest risk of complication should be used after obtaining informed consent. This will allow one to maximize the diagnostic efficiency while also limiting the adverse effects.",
keywords = "Diagnostic imaging, Gadolinium, Kidney disease, Nephrogenic systemic fibrosis, Radiocontrast-induced nephropathy",
author = "Perazella, {Mark A.} and Reilly, {Robert F.}",
year = "2011",
month = "3",
doi = "10.1097/MAJ.0b013e3181f016e6",
language = "English (US)",
volume = "341",
pages = "215--221",
journal = "The American journal of the medical sciences",
issn = "0002-9629",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Imaging patients with kidney disease

T2 - How do we approach contrast-related toxicity?

AU - Perazella, Mark A.

AU - Reilly, Robert F.

PY - 2011/3

Y1 - 2011/3

N2 - The approach to imaging patients with kidney disease with iodinated radiocontrast and gadolinium-based contrast has changed dramatically in recent times. The complications of these contrast agents, radiocontrast nephropathy and nephrogenic systemic fibrosis, respectively, underlie the changes in the imaging practice used in these patients. Rather than to completely avoid the use of these contrast agents, one must remain judicious in the choice of imaging modality in this group of patients. A prudent approach would be to (1) identify patients at high risk to develop contrast-related complications, (2) use noncontrast-based imaging techniques in these patients, as long as they are suitably diagnostic and safe and (3) if the risk:benefit ratio of the imaging information favors a contrast-based study, then appropriate prophylactic steps and use of contrast agents with the lowest risk of complication should be used after obtaining informed consent. This will allow one to maximize the diagnostic efficiency while also limiting the adverse effects.

AB - The approach to imaging patients with kidney disease with iodinated radiocontrast and gadolinium-based contrast has changed dramatically in recent times. The complications of these contrast agents, radiocontrast nephropathy and nephrogenic systemic fibrosis, respectively, underlie the changes in the imaging practice used in these patients. Rather than to completely avoid the use of these contrast agents, one must remain judicious in the choice of imaging modality in this group of patients. A prudent approach would be to (1) identify patients at high risk to develop contrast-related complications, (2) use noncontrast-based imaging techniques in these patients, as long as they are suitably diagnostic and safe and (3) if the risk:benefit ratio of the imaging information favors a contrast-based study, then appropriate prophylactic steps and use of contrast agents with the lowest risk of complication should be used after obtaining informed consent. This will allow one to maximize the diagnostic efficiency while also limiting the adverse effects.

KW - Diagnostic imaging

KW - Gadolinium

KW - Kidney disease

KW - Nephrogenic systemic fibrosis

KW - Radiocontrast-induced nephropathy

UR - http://www.scopus.com/inward/record.url?scp=79952071552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952071552&partnerID=8YFLogxK

U2 - 10.1097/MAJ.0b013e3181f016e6

DO - 10.1097/MAJ.0b013e3181f016e6

M3 - Article

C2 - 21139495

AN - SCOPUS:79952071552

VL - 341

SP - 215

EP - 221

JO - The American journal of the medical sciences

JF - The American journal of the medical sciences

SN - 0002-9629

IS - 3

ER -